Race Oncology Ltd (ASX:RAC) executive director Pete Smith speaks with Proactive alongside the company’s recently appointed CEO - 25-year veteran of the biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillett will work closely with Dr Smith to steer the company's strategic, clinical and commercialisation efforts, with a primary focus on advancing bisantrene. Dr Tillett is already well acquainted with the cancer-targeting biotech firm. From September 2019 to March 2023, he served as Race's chief scientific officer and executive director, playing a crucial role in the company's growth and development. After this initial tenure, he continued to contribute to Race in a consultancy capacity.
“My priority in stepping in as CEO is to ensure the clinical strategy we have for bisantrene is implemented and our promise to shareholders delivered. My belief in bisantrene and its commercial potential has never wavered," Dr Tillett said. “We have an outstanding team at Race to execute on these opportunities and make a real difference for both patients and shareholders."
Contact Details
Proactive Investors
Gregg Castano
+1 203-762-5649
gregg.castano@newsdirect.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.